Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alphatec launches spinal bridge

This article was originally published in The Gray Sheet

Executive Summary

Firm announces availability of its 510(k)-cleared Cross Link adjustable bridge spinal implant on July 18. The device, which Alphatec acquired through a distribution agreement with Sea Spine, will be marketed for use in combination with the firm's Zodiac polyaxial pedical screws. Alphatec went public in June, to compete with Stryker, Smith & Nephew and Abbott in the almost $3 bil. spinal fusion market (1"The Gray Sheet" July 17, 2006, p. 9)...

You may also be interested in...



Orthopedics In Brief

Medtronic set to begin spinal stabilization trial: Firm is enrolling patients for the first of three clinical trials evaluating the use of its Diam spinal stabilization system. Medtronic announced IDE clearance to begin studies of the nonfusion spinal stabilization system on July 10. Diam relieves spine pressure by rerouting spinal load, similar to St. Francis Medical's X-Stop device, PMA approved in 2005. Medtronic's initial study, slated to begin in August, will examine the safety and effectiveness of the Diam system in patients with degenerative stenosis. The second trial, to begin in Europe in September, will compare discectomy with Diam to discectomy alone. A third study will evaluate Diam's use in degenerative disc disease. Medtronic expects to enroll a total of 430 patients in up to 25 centers in the U.S. and Europe...

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.

UsernamePublicRestriction

Register

MT023789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel